Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2013-12, Vol.31 (50), p.6011-6021 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6021 |
|---|---|
| container_issue | 50 |
| container_start_page | 6011 |
| container_title | Vaccine |
| container_volume | 31 |
| creator | Cho, Bo-Hyun Stoecker, Charles Link-Gelles, Ruth Moore, Matthew R |
| description | Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in other populations with worse vaccine efficacy or serotype match. |
| doi_str_mv | 10.1016/j.vaccine.2013.10.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516750566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X1301400X</els_id><sourcerecordid>1459972162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-aed99198cbaca4e1f0286bd7e6df459b77d1a53c59b0c0dec569ea55ca5745cc3</originalsourceid><addsrcrecordid>eNqNkl-L1DAUxYso7rj6EdSCCL50zE2b_nlRZPAfLPiwLuxbyCS3sxnbZDZpR-aL-fm8paMDi7A-JYTfOTm5OUnyHNgSGJRvt8u90to6XHIGOZ0tGS8eJAuoqzzjAuqHyYLxssgKYNdnyZMYt4wxkUPzODnjBRS1qPgi-bXycciwbVEPdo8OY0x9myrTW2fjgMG6TQp5tlcduiHdORx7r73Wqku1d9txowZMj1FS60hp7GC9Swef8n_rdr47RFLcqGDNSUwCZcZuiOlPO9yktu9HR5J-F3xv45SDLpzN49PkUau6iM-O63ly9enj99WX7OLb56-rDxeZFmU9ZApN00BT67XSqkBoGa_LtamwNG0hmnVVGVAi17RlmhkkVYNKCK1EVQit8_PkzexLIW5HjIOkKBq7Tjn0Y5QgoKwEE2X5HyhNP2_KCu5HKVtTcSg5oa_uoFs_BkdvJkPB65pDI4gSM6WDjzFgK3fB9iocJDA51UVu5XHMcqrLdEx1Id2Lo_u47tH8Vf3pBwGvj4CK9HVtUE7beOJqBqyqpxe9nLlWeak2gZirS7pJMAZVw2Ei3s8E0nftLQYZtUWn0dhA3ZPG23vDvrvjoDsqKcX6gQeMp7nIyCWTl1P7p_JDzqBg7Dr_DUj5Aug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552882195</pqid></control><display><type>article</type><title>Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cho, Bo-Hyun ; Stoecker, Charles ; Link-Gelles, Ruth ; Moore, Matthew R</creator><creatorcontrib>Cho, Bo-Hyun ; Stoecker, Charles ; Link-Gelles, Ruth ; Moore, Matthew R</creatorcontrib><description>Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in other populations with worse vaccine efficacy or serotype match.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2013.10.024</identifier><identifier>PMID: 24148572</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Acquired immune deficiency syndrome ; Adult ; adults ; Aged ; AIDS ; Allergy and Immunology ; Applied microbiology ; Bacteriology ; Biological and medical sciences ; cost effectiveness ; Cost-Benefit Analysis ; disease incidence ; Female ; Fundamental and applied biological sciences. Psychology ; HIV infections ; Human immunodeficiency virus ; Humans ; Immunization ; Immunocompromised adults ; Immunocompromised Host ; immunocompromised population ; Incremental cost-effectiveness ; kidney diseases ; Male ; Microbiology ; Middle Aged ; Miscellaneous ; Models, Statistical ; Observational studies ; organ transplantation ; PCV13 ; Pneumococcal Infections - economics ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - administration & dosage ; Pneumococcal Vaccines - economics ; Pneumonia ; probabilistic models ; Public health ; quality-adjusted life year ; randomized clinical trials ; risk ; Streptococcus pneumoniae ; Transplants & implants ; United States ; vaccination ; Vaccination - economics ; Vaccination - methods ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Young Adult</subject><ispartof>Vaccine, 2013-12, Vol.31 (50), p.6011-6021</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Dec 5, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-aed99198cbaca4e1f0286bd7e6df459b77d1a53c59b0c0dec569ea55ca5745cc3</citedby><cites>FETCH-LOGICAL-c568t-aed99198cbaca4e1f0286bd7e6df459b77d1a53c59b0c0dec569ea55ca5745cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X1301400X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28010781$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24148572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cho, Bo-Hyun</creatorcontrib><creatorcontrib>Stoecker, Charles</creatorcontrib><creatorcontrib>Link-Gelles, Ruth</creatorcontrib><creatorcontrib>Moore, Matthew R</creatorcontrib><title>Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in other populations with worse vaccine efficacy or serotype match.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>adults</subject><subject>Aged</subject><subject>AIDS</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>cost effectiveness</subject><subject>Cost-Benefit Analysis</subject><subject>disease incidence</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV infections</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunocompromised adults</subject><subject>Immunocompromised Host</subject><subject>immunocompromised population</subject><subject>Incremental cost-effectiveness</subject><subject>kidney diseases</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Models, Statistical</subject><subject>Observational studies</subject><subject>organ transplantation</subject><subject>PCV13</subject><subject>Pneumococcal Infections - economics</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumococcal Vaccines - economics</subject><subject>Pneumonia</subject><subject>probabilistic models</subject><subject>Public health</subject><subject>quality-adjusted life year</subject><subject>randomized clinical trials</subject><subject>risk</subject><subject>Streptococcus pneumoniae</subject><subject>Transplants & implants</subject><subject>United States</subject><subject>vaccination</subject><subject>Vaccination - economics</subject><subject>Vaccination - methods</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkl-L1DAUxYso7rj6EdSCCL50zE2b_nlRZPAfLPiwLuxbyCS3sxnbZDZpR-aL-fm8paMDi7A-JYTfOTm5OUnyHNgSGJRvt8u90to6XHIGOZ0tGS8eJAuoqzzjAuqHyYLxssgKYNdnyZMYt4wxkUPzODnjBRS1qPgi-bXycciwbVEPdo8OY0x9myrTW2fjgMG6TQp5tlcduiHdORx7r73Wqku1d9txowZMj1FS60hp7GC9Swef8n_rdr47RFLcqGDNSUwCZcZuiOlPO9yktu9HR5J-F3xv45SDLpzN49PkUau6iM-O63ly9enj99WX7OLb56-rDxeZFmU9ZApN00BT67XSqkBoGa_LtamwNG0hmnVVGVAi17RlmhkkVYNKCK1EVQit8_PkzexLIW5HjIOkKBq7Tjn0Y5QgoKwEE2X5HyhNP2_KCu5HKVtTcSg5oa_uoFs_BkdvJkPB65pDI4gSM6WDjzFgK3fB9iocJDA51UVu5XHMcqrLdEx1Id2Lo_u47tH8Vf3pBwGvj4CK9HVtUE7beOJqBqyqpxe9nLlWeak2gZirS7pJMAZVw2Ei3s8E0nftLQYZtUWn0dhA3ZPG23vDvrvjoDsqKcX6gQeMp7nIyCWTl1P7p_JDzqBg7Dr_DUj5Aug</recordid><startdate>20131205</startdate><enddate>20131205</enddate><creator>Cho, Bo-Hyun</creator><creator>Stoecker, Charles</creator><creator>Link-Gelles, Ruth</creator><creator>Moore, Matthew R</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20131205</creationdate><title>Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions</title><author>Cho, Bo-Hyun ; Stoecker, Charles ; Link-Gelles, Ruth ; Moore, Matthew R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-aed99198cbaca4e1f0286bd7e6df459b77d1a53c59b0c0dec569ea55ca5745cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>adults</topic><topic>Aged</topic><topic>AIDS</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>cost effectiveness</topic><topic>Cost-Benefit Analysis</topic><topic>disease incidence</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV infections</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunocompromised adults</topic><topic>Immunocompromised Host</topic><topic>immunocompromised population</topic><topic>Incremental cost-effectiveness</topic><topic>kidney diseases</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Models, Statistical</topic><topic>Observational studies</topic><topic>organ transplantation</topic><topic>PCV13</topic><topic>Pneumococcal Infections - economics</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumococcal Vaccines - economics</topic><topic>Pneumonia</topic><topic>probabilistic models</topic><topic>Public health</topic><topic>quality-adjusted life year</topic><topic>randomized clinical trials</topic><topic>risk</topic><topic>Streptococcus pneumoniae</topic><topic>Transplants & implants</topic><topic>United States</topic><topic>vaccination</topic><topic>Vaccination - economics</topic><topic>Vaccination - methods</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, Bo-Hyun</creatorcontrib><creatorcontrib>Stoecker, Charles</creatorcontrib><creatorcontrib>Link-Gelles, Ruth</creatorcontrib><creatorcontrib>Moore, Matthew R</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, Bo-Hyun</au><au>Stoecker, Charles</au><au>Link-Gelles, Ruth</au><au>Moore, Matthew R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2013-12-05</date><risdate>2013</risdate><volume>31</volume><issue>50</issue><spage>6011</spage><epage>6021</epage><pages>6011-6021</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Highlights • We model the cost effectiveness of PCV for adults with immunocompromising conditions. • We find the recommendation to be cost saving on the whole. • The recommendation saves $7 million per cohort. • This savings is largely from adults with end state renal disease. • Savings are less in other populations with worse vaccine efficacy or serotype match.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24148572</pmid><doi>10.1016/j.vaccine.2013.10.024</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2013-12, Vol.31 (50), p.6011-6021 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516750566 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acquired immune deficiency syndrome Adult adults Aged AIDS Allergy and Immunology Applied microbiology Bacteriology Biological and medical sciences cost effectiveness Cost-Benefit Analysis disease incidence Female Fundamental and applied biological sciences. Psychology HIV infections Human immunodeficiency virus Humans Immunization Immunocompromised adults Immunocompromised Host immunocompromised population Incremental cost-effectiveness kidney diseases Male Microbiology Middle Aged Miscellaneous Models, Statistical Observational studies organ transplantation PCV13 Pneumococcal Infections - economics Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumonia probabilistic models Public health quality-adjusted life year randomized clinical trials risk Streptococcus pneumoniae Transplants & implants United States vaccination Vaccination - economics Vaccination - methods Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Young Adult |
| title | Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A02%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20administering%2013-valent%20pneumococcal%20conjugate%20vaccine%20in%20addition%20to%2023-valent%20pneumococcal%20polysaccharide%20vaccine%20to%20adults%20with%20immunocompromising%20conditions&rft.jtitle=Vaccine&rft.au=Cho,%20Bo-Hyun&rft.date=2013-12-05&rft.volume=31&rft.issue=50&rft.spage=6011&rft.epage=6021&rft.pages=6011-6021&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2013.10.024&rft_dat=%3Cproquest_cross%3E1459972162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552882195&rft_id=info:pmid/24148572&rft_els_id=S0264410X1301400X&rfr_iscdi=true |